Introduction: To date, several emerging biomarkers have gained considerable interest in the field of predictive molecular oncology. The advent of precision medicine has led to the development of innovative drugs targeting rare molecular pathways independently from histology, defined as tissue-agnostic drugs. Areas covered: Although there is a lot of promise for this new tissue-agnostic model in the oncological scenario, crucial issues from both the diagnostic and therapeutic standpoint are emerging. This review aims to critically examine the role of tissue-agnostic biomarkers in different solid tumors, focusing on the prevalence and methods of detection of agnostic biomarkers together with drug approvals to guide clinicians in this evolving landscape. Expert opinion: To strengthen the framework for tissue-agnostic approvals, the dialogue between regulatory, industrial, and academic parties should be intensified. Critical questions include the development of an efficient network system that can overcome the heterogeneity of patients’ inclusion criteria along with the increasingly difficult interpretation of next-generation sequencing (NGS) profiling technologies. Cost-effectiveness and risk–benefit studies are needed in the national context considering the modalities of access to diagnostic tests and reimbursement of treatments.

Gristina V., Pisapia P., Barraco N., Pepe F., Iacono F., La Mantia M., et al. (2023). The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 23(10), 851-861 [10.1080/14737159.2023.2245752].

The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?

Gristina V.;Barraco N.;La Mantia M.;Peri M.;Galvano A.;Incorvaia L.;Badalamenti G.;Bazan V.;Russo A.;
2023-08-08

Abstract

Introduction: To date, several emerging biomarkers have gained considerable interest in the field of predictive molecular oncology. The advent of precision medicine has led to the development of innovative drugs targeting rare molecular pathways independently from histology, defined as tissue-agnostic drugs. Areas covered: Although there is a lot of promise for this new tissue-agnostic model in the oncological scenario, crucial issues from both the diagnostic and therapeutic standpoint are emerging. This review aims to critically examine the role of tissue-agnostic biomarkers in different solid tumors, focusing on the prevalence and methods of detection of agnostic biomarkers together with drug approvals to guide clinicians in this evolving landscape. Expert opinion: To strengthen the framework for tissue-agnostic approvals, the dialogue between regulatory, industrial, and academic parties should be intensified. Critical questions include the development of an efficient network system that can overcome the heterogeneity of patients’ inclusion criteria along with the increasingly difficult interpretation of next-generation sequencing (NGS) profiling technologies. Cost-effectiveness and risk–benefit studies are needed in the national context considering the modalities of access to diagnostic tests and reimbursement of treatments.
8-ago-2023
Gristina V., Pisapia P., Barraco N., Pepe F., Iacono F., La Mantia M., et al. (2023). The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 23(10), 851-861 [10.1080/14737159.2023.2245752].
File in questo prodotto:
File Dimensione Formato  
The significance of tissue agnostic biomarkers in solid tumors the more the merrier.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 1.42 MB
Formato Adobe PDF
1.42 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/621536
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact